Qualigen Soars 31.88% on $41M Faraday Future Deal and Crypto Pivot – What’s Next for This Biotech Turned Web3 Play?

Summary
• Qualigen (QLGN) surges 31.88% to $5.46, hitting an intraday high of $6.48 after a $41M investment from Faraday Future.
• The deal includes a 55% stake for FF and a strategic pivot to crypto/Web3 infrastructure.
• Technicals show a short-term bullish trend with RSI at 72.62 and MACD above signal line.

Qualigen Therapeutics (QLGN) has ignited a 31.88% rally on September 25, 2025, driven by a transformative $41M investment from Faraday Future and a bold pivot to blockchain. The stock’s intraday high of $6.48 reflects a dramatic shift in market sentiment, fueled by regulatory clarity, capital infusion, and a rebranding strategy targeting crypto ecosystems. With technical indicators flashing bullish signals and sector peers like Nvidia (NVDA) rising 0.13%, the move raises critical questions about sustainability and risk-reward dynamics.

Faraday’s $41M Lifeline and Crypto Pivot Ignite Biotech Turnaround
Qualigen’s 31.88% surge stems from a $41M private investment in public equity (PIPE) led by Faraday Future, granting the EV maker 55% ownership and a strategic pivot to crypto/Web3 infrastructure. The deal, announced at Faraday’s 919 event, includes a $30M investment from FF, a $4M loan from FFGP for YT Jia’s 7% stake, and participation from blockchain firm SIGN Foundation. This capital infusion not only extends Qualigen’s runway but also signals validation from high-profile Web3-aligned investors. The rebranding to CXC10 and focus on crypto infrastructure—targeting three growth engines with six potential products—has repositioned the stock as a hybrid biotech/Web3 play, attracting speculative buyers and institutional attention.

Blockchain Sector Rally Amplifies QLGN’s Momentum
The blockchain sector has surged alongside QLGN’s rally, with Nvidia (NVDA) rising 0.13% as a sector leader. While QLGN operates in biotech, its pivot to crypto aligns it with blockchain peers like Binance (BNB) and Ethereum (ETH), which have seen renewed institutional interest. The sector’s 72% rise in DeFi lending and tokenized RWAs underscores growing appetite for crypto infrastructure, positioning QLGN’s pivot as a strategic move to tap into this trend. However, QLGN’s biotech roots remain a wildcard, with its oncology pipeline (QN-302, Pan-RAS) still in early-stage trials.

Technical Setup and ETF Alignment for QLGN’s Volatile Play
• MACD: 0.505 (above signal line 0.194), RSI: 72.62 (overbought), Bollinger Bands: Upper $4.47, Middle $2.38, Lower $0.28
• 200D MA: $3.295 (below current price), Support/Resistance: 30D $1.82–$1.90, 200D $3.75–$3.83

QLGN’s technicals suggest a short-term bullish breakout, with RSI nearing overbought territory and MACD crossing above the signal line. The stock is trading above its 200-day MA ($3.295) and within a wide Bollinger Band range, indicating high volatility. Key support at $3.75–$3.83 (200D) and resistance at $4.47 (upper band) define the near-term trading range. While no leveraged ETFs are available, the stock’s 800.73% turnover rate and 31.88% intraday gain highlight liquidity and momentum. With no options data provided, traders should focus on technical levels: a break above $6.48 (intraday high) could trigger a retest of the 52-week high ($10.45), while a pullback to $3.75 (200D MA) may offer a second-chance entry. Position sizing should reflect the stock’s high beta (-0.15) and speculative nature.

Backtest Qualigen Stock Performance
We ran into a technical problem when the event-level back-test engine tried to process the surge dates list (“convert_statistics” failed). Likely causes:• The surge-date file may contain zero or very few valid events because of the way we originally defined “32 % intraday surge” (we used yesterday’s high/low instead of the same-day range). • The back-test engine throws an error when it receives an empty or malformed event list.Recommended recovery plan1. Re-detect 32 % intraday surges the usual way: (same-day high − same-day low) ÷ same-day low ≥ 0.32.2. Re-generate the event-date file with that rule (no extra MACD / follow-through filters, unless you prefer to keep them).3. Re-run the event back-test engine on the corrected date set, or, if you prefer, run a simpler test such as: • Buy at the next-day open after a surge • Close after N trading days (e.g., 1-day, 5-day and 20-day windows) • Benchmark vs. buy-and-hold.Please let me know:A. Keep the surge rule exactly as “high-low vs. low ≥ 32 %”, or add any extra filters (MACD > 0, close > previous high, etc.)? B. Preferred holding window(s) for the post-surge performance (next-day close only, 5-day, 20-day, or other)? C. Any risk controls (stop-loss / take-profit) you’d like to include?Once I have your preferences I’ll regenerate the event list and re-run the back-test.

QLGN’s Hybrid Play: Biotech Breakthrough or Web3 Hype?
Qualigen’s 31.88% surge reflects a high-stakes gamble on a biotech-to-Web3 pivot, backed by Faraday Future’s $41M investment. While the oncology pipeline (QN-302, Pan-RAS) remains unproven, the crypto infrastructure pivot taps into a sector gaining institutional traction. Traders should monitor the $3.75 (200D MA) support and $6.48 (intraday high) resistance, with a watch on sector leader Nvidia (NVDA) rising 0.13%. A sustained break above $6.48 could validate the bullish case, but a retest of $3.75 may test conviction. For now, QLGN’s asymmetric risk-reward profile—capped downside from the capital infusion and unlimited upside from either scientific or crypto-driven catalysts—makes it a high-volatility play for aggressive investors.